A novel mutation in EROS (CYBC1) causes chronic granulomatous disease
Clinical Immunology · 2023
DOI: 10.1016/j.clim.2023.109761 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Immunology, 2023. Verfasst von Paige M Mortimer und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, United Kingdom. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Wellcome Trust, Department of Health, National Institutes of Health.
Abstract (Originalsprache)
Chronic Granulomatous Disease (CGD) is an inborn error of immunity characterised by opportunistic infection and sterile granulomatous inflammation. CGD is caused by a failure of reactive oxygen species (ROS) production by the phagocyte NADPH oxidase. Mutations in the genes encoding phagocyte NADPH oxidase subunits cause CGD. We and others have described a novel form of CGD (CGD5) secondary to lack of EROS (CYBC1), a highly selective chaperone for gp91phox. EROS-deficient cells express minimal levels of gp91phox and its binding partner p22phox, but EROS also controls the expression of other proteins such as P2X7. The full nature of CGD5 is currently unknown. We describe a homozygous frameshift mutation in CYBC1 leading to CGD. Individuals who are heterozygous for this mutation are found in South Asian populations (allele frequency = 0.00006545), thus it is not a private mutation. Therefore, it is likely to be the underlying cause of other cases of CGD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, United Kingdom.
- Aster Medcity Hospital, Kochi, Kerala, India.
- Aster CMI Hospital, Bangalore, India.
- Wellcome Sanger Institute, Hinxton, United Kingdom.
- Clinical Development, Late Respiratory and Immunology, BioPharmaceuticals R and D, AstraZeneca, Cambridge, United Kingdom.
- Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, United Kingdom. Electronic address: tdct2@cam.ac.uk.
Förderung
- Wellcome Trust
- Department of Health
- National Institutes of Health
- National Institute for Health and Care Research
- Imperial College London
Zitieren
APA
Mortimer, P. M., Nichols, E., Thomas, J., Shanbhag, R., Singh, N., Coomber, E. L., Malik, T. H., Pickering, M. C., Randzavola, L., Rae, W., Bhattad, S., & Thomas, D. C. (2023). A novel mutation in EROS (CYBC1) causes chronic granulomatous disease. Clinical Immunology. https://doi.org/10.1016/j.clim.2023.109761
Vancouver
Mortimer PM, Nichols E, Thomas J, Shanbhag R, Singh N, Coomber EL, et al. A novel mutation in EROS (CYBC1) causes chronic granulomatous disease. Clinical Immunology. 2023. doi:10.1016/j.clim.2023.109761
BibTeX
@article{Mortimer2023,
author = {Mortimer, Paige M and Nichols, Esme and Thomas, Joe and Shanbhag, Rachna and Singh, Neha and Coomber, Eve L and Malik, Talat H and Pickering, Matthew C and Randzavola, Lyra and Rae, William and Bhattad, Sagar and Thomas, David C},
title = {A novel mutation in EROS (CYBC1) causes chronic granulomatous disease},
journal = {Clinical Immunology},
year = {2023},
doi = {10.1016/j.clim.2023.109761}
}
EUVIMED